Antibiotic resistance market growth outlook through 2030

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Antibiotic Resistance Market Expected To Scale Between 2026 And 2030?

The antibiotic resistance market has experienced robust expansion in recent years. This market is projected to expand from $12.85 billion in 2025 to $13.73 billion in 2026, achieving a compound annual growth rate (CAGR) of 6.8%. Historically, this growth has been driven by factors such as widespread antibiotic misuse, increasing hospital-acquired infections, expansion of broad-spectrum antibiotic use, limited availability of novel antibiotics, and a rising prevalence of resistant pathogens.

The antibiotic resistance market is anticipated to show strong expansion in the upcoming years. It is projected to grow to $18.22 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 7.3%. This growth during the forecast period can be attributed to increased investments in antimicrobial R&D, a broader adoption of precision diagnostics, the enlargement of global resistance surveillance networks, a rising emphasis on alternative therapies, and an increase in public-private partnerships. Major trends anticipated in the forecast period include a heightened focus on novel antibiotic development, the increasing use of combination drug therapies, wider implementation of rapid diagnostic testing, the expansion of antimicrobial stewardship programs, and improved surveillance of resistant pathogens.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/report/antibiotic-resistance-global-market-report

Which Major Drivers Are Influencing The Expansion Of The Antibiotic Resistance Market?

The escalating incidence of drug-resistant infections is projected to fuel the expansion of the antibiotic-resistance market moving forward. Such infections are illnesses caused by resistant bacteria, leading to a condition that is considerably more challenging or impossible to cure. Antimicrobial resistance medications assist in treating various drug-resistant infections, delivering improved antibiotic treatment outcomes for both targeted and non-targeted pathogens, depending on the specifics of resistance mechanisms and the interaction structure of the microbiome community. For illustration, in November 2025, as reported by the UK Health Security Agency, a UK-based government organization responsible for all health security in England, the count of fatalities among individuals with antibiotic-resistant infections increased from 2,041 in 2023 to 2,379 in 2024, signifying a jump of 338 deaths within a single year. Thus, the widespread occurrence of drug-resistant infections is a key factor driving the antibiotic resistance market.

How Are Segments Identified Within The Antibiotic Resistance Market Segment Framework?

The antibiotic resistance market covered in this report is segmented –

1) By Drug Class: Beta Lactum Antibiotic, Cephalosporins, Quinolones Antibiotics, Macrolide Antibiotics, Tetracyclines, Oxazolidinones, Other Drug Classes

2) By Pathogen: Staphylococcus Aureus, Staphylococcus Pneumonia, Neisseria Gonorrhoeae, Enterococcus Faecium, Escherichia Coli, Klebsiella Pneumonia, Shigella, Clostridium Difficile, Other Pathogens

3) By Disease Type: Urinary Tract Infection, Intra-Abdominal Infection, Blood Stream infections, Clostridium Difficile Infections, Other Disease Types

4) By Mechanism Of Action: Protein Synthesis Inhibitors, Cell Wall Synthesis Inhibitors, RNA Synthesis Inhibitors, DNA Synthesis Inhibitors, Other Mechanism Of Actions

5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End-users

Subsegments:

1) By Beta Lactam Antibiotics: Penicillins, Cephalosporins, Carbapenems, Monobactams

2) By Cephalosporins: First-generation, Second-generation, Third-generation, Fourth-generation

3) By Quinolones Antibiotics: Fluoroquinolones, Other Quinolones

4) By Macrolide Antibiotics: Erythromycin, Azithromycin, Clarithromycin

5) By Tetracyclines: Doxycycline, Minocycline, Tetracycline

6) By Oxazolidinones: Linezolid, Tedizolid

7) By Other Drug Classes: Glycopeptides, Lipopeptides, Streptogramins, Polymyxins

Which Trends Are Shaping The Antibiotic Resistance Market?

Companies operating within the antibiotic resistance market are primarily focused on developing novel products to improve treatment effectiveness, guarantee patient safety, and address the growing issue of multi-drug resistant (MDR) infections. An illustrative example occurred in January 2023, when Alkem Laboratories Limited, an India-based pharmaceutical firm, launched Zidavi, an innovative antibiotic designed to combat MDR infections, thereby enhancing its availability, affordability, and accessibility while aiming to save the lives of critically ill patients. Zidavi represents a unique blend of ceftazidime and avibactam capable of treating infections caused by MDR gram-negative pathogens. It is provided as a sterile powdered concentrate requiring reconstitution, with each single-dose vial comprising ceftazidime pentahydrate equivalent to 2 g of ceftazidime and avibactam sodium equivalent to 0.5 g of avibactam. This medication offers an effective alternative for addressing hospital-acquired pneumonia (HAP) and severe intra-abdominal infections (IAIs) that are resistant to meropenem and colistin.

Who Are The Companies Competing Within The Antibiotic Resistance Market?

Major companies operating in the antibiotic resistance market are Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, AbbVie Inc., Novartis AG, Merck and Co. Inc., Bristol-Myers Squibb, Sanofi S.A., AstraZeneca, GlaxoSmithKline Plc, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Astellas Pharma, Daiichi Sankyo, Chugai Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Paratek Pharmaceuticals Inc., Basilea Pharmaceutica Ltd., Theravance Biopharma Inc., Nabriva Therapeutics Plc, Seres Therapeutics Inc., Armata Pharmaceuticals Inc.

Get The Full Antibiotic Resistance Market Report:

https://www.thebusinessresearchcompany.com/report/antibiotic-resistance-global-market-report

Which Region Leads The Antibiotic Resistance Market In Overall Market Size?

North America was the largest region in the antibiotic resistance market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the antibiotic resistance market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Antibiotic Resistance Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/antibiotic-resistance-global-market-report

Browse Through More Reports Similar to the Global Antibiotic Resistance Market 2026, By The Business Research Company

Veterinary Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/veterinary-antibiotics-global-market-report

Multidrug Resistant Bacteria Market Report 2026

https://www.thebusinessresearchcompany.com/report/multidrug-resistant-bacteria-global-market-report

Antibiotics Market Report 2026

https://www.thebusinessresearchcompany.com/report/antibiotics-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795